First CRISPR Patent in U.S Goes To MilliporeSigma
MilliporeSigma has bagged the first CRISPR patent in the United States. The U.S. Patent and Trademark Office has issued a formal Notice allowing MilliporeSigma’s application directed to its proxy-CRISPR technology.
MilliporeSigma CEO – Udit Batra in a statement said that this news will be embraced by the researchers in the U.S as numerous gene editing options now exist that can lead to accelerated drug discovery & developments. He further added that MilliporeSigma being a leading innovator of CRISPR Tech with 15 years’ experience in genome editing & discovery- is open to collaborating with scientists globally with an aim to unleash Proxy-CRISPR Tech’s full potential and its ethical usage.
About Proxy-CRISPR, its the latest gene editing technique specifically designed to enhance the efficiency, speed, and specificity of CRISPR tech by nicking the genome for DNA Modification. As MilliporeSigmaper, with the help of this tech, researchers can gain access to regions of the genome that are hard to reach
Proxy-CRISPR by MilliporeSigma utilizes two CRISPR systems developed specifically to act on the genome in proximity to each other. One CRISPR system opens a regional “door,” pushing away blocking chromatin proteins, while the other walks through it to find the exact location for modification. Since this
tech involves two CRISPR system, twice the specificity of individual CRISPR system can be achieved.The U.S. patent allowance marks MilliporeSigma’s 13th CRISPR patent Globally.
The company was granted patents for technologies that were CRISPR-related covering alternative and foundational techniques starting in June 2017 in Australia, two months later in Europe. In Australia and Europe as well as in Canada, MilliporeSigma has received patents for its CRISPR paired nickase technology, which utilizes cleaving opposite strands of a chromosomal order to make a double-stranded fracture –as well as for CRISPR integration technologies, which entails the chromosomal cutting of this sequence of eukaryotic cells and insertion of a DNA sequence.
MilliporeSigma’s CRISPR patent portfolio includes granted patents in Australia, Canada, Europe, Singapore, China, Israel, and South Korea
MilliporeSigma will be licensing its entire patent portfolio for usage in all fields.
As both users and suppliers of genome-editing technology, the businesses of Merck KGaA, Darmstadt, Germany support research with genome editing under careful consideration of ethical and legal standards. Merck KGaA, Darmstadt, Germany has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
Press Release By MilliporeSigma
